Ignite Creation Date:
2025-12-25 @ 4:51 AM
Ignite Modification Date:
2025-12-26 @ 3:52 AM
Study NCT ID:
NCT05615818
Status:
RECRUITING
Last Update Posted:
2025-04-23
First Post:
2022-10-28
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Personalized Medicine for Advanced Biliary Cancer Patients
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D001661', 'term': 'Biliary Tract Neoplasms'}], 'ancestors': [{'id': 'D004067', 'term': 'Digestive System Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D001660', 'term': 'Biliary Tract Diseases'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000713257', 'term': 'futibatinib'}, {'id': 'C000627630', 'term': 'ivosidenib'}, {'id': 'C000726995', 'term': 'zanidatamab'}, {'id': 'D000068878', 'term': 'Trastuzumab'}, {'id': 'C487932', 'term': 'neratinib'}, {'id': 'C000601108', 'term': 'encorafenib'}, {'id': 'C581313', 'term': 'binimetinib'}, {'id': 'C545685', 'term': 'niraparib'}, {'id': 'D002945', 'term': 'Cisplatin'}, {'id': 'D000093542', 'term': 'Gemcitabine'}], 'ancestors': [{'id': 'D061067', 'term': 'Antibodies, Monoclonal, Humanized'}, {'id': 'D000911', 'term': 'Antibodies, Monoclonal'}, {'id': 'D000906', 'term': 'Antibodies'}, {'id': 'D007136', 'term': 'Immunoglobulins'}, {'id': 'D007162', 'term': 'Immunoproteins'}, {'id': 'D001798', 'term': 'Blood Proteins'}, {'id': 'D011506', 'term': 'Proteins'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}, {'id': 'D012712', 'term': 'Serum Globulins'}, {'id': 'D005916', 'term': 'Globulins'}, {'id': 'D017606', 'term': 'Chlorine Compounds'}, {'id': 'D007287', 'term': 'Inorganic Chemicals'}, {'id': 'D017672', 'term': 'Nitrogen Compounds'}, {'id': 'D017671', 'term': 'Platinum Compounds'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D003841', 'term': 'Deoxycytidine'}, {'id': 'D003562', 'term': 'Cytidine'}, {'id': 'D011741', 'term': 'Pyrimidine Nucleosides'}, {'id': 'D011743', 'term': 'Pyrimidines'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 800}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2024-07-18', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2024-11', 'completionDateStruct': {'date': '2028-06', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-04-22', 'studyFirstSubmitDate': '2022-10-28', 'studyFirstSubmitQcDate': '2022-11-07', 'lastUpdatePostDateStruct': {'date': '2025-04-23', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2022-11-14', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2027-06', 'type': 'ESTIMATED'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'Feasibility of molecular screening', 'timeFrame': 'Up to 3 months from start of treatment', 'description': 'The proportion of patients with an available MTB proposition at the time of the 3-month standard of care treatment evaluation.'}, {'measure': 'Quality of life questionnaire - Core 30 (QLQ-C30)', 'timeFrame': 'From baseline, every 3 cycles (every 9 weeks) until end of treatment, an average of 1 year', 'description': 'Developed by the EORTC, this self-reported questionnaire assesses the health-related quality of life of cancer patients in clinical trials.\n\nThe questionnaire includes five functional scales (physical, everyday activity, cognitive, emotional, and social), three symptom scales (fatigue, pain, nausea and vomiting), a health/quality of life overall scale, and a number of additional elements assessing common symptoms (including dyspnea, loss of appetite, insomnia, constipation, and diarrhea), as well as, the perceived financial impact of the disease.\n\nAll of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.'}, {'measure': 'Quality of life Questionnaire - Biliary tract cancer module (QLQ-BIL21)', 'timeFrame': 'From baseline, every 3 cycles (every 9 weeks) until end of treatment, an average of 1 year', 'description': 'This EORTC cholangiocarcinoma and gallbladder cancer specific questionnaire is intended to supplement the QLQ-C30.\n\nThe QLQ-BIL21 contains 21 items to assess symptoms. All items are rated on a four-point Likert-type scale (1 = "not at all", 2 = "a little", 3 = "quite a bit", and 4 = "very much"), and are linearly transformed to a 0-100 scale.'}, {'measure': 'EuroQOL EQ-5D-5L questionnaire', 'timeFrame': 'From baseline, every 3 cycles (every 9 weeks) until end of treatment, an average of 1 year', 'description': 'Developed by the EuroQol group, the self-reported questionnaire assesses the health-related quality of life of cancer patients in clinical trials consists of a descriptive system and a visual analogue scale (VAS).\n\nThe EQ-5D-5L descriptive system comprises five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each dimension has 5 levels (1 = "no problems", 2 = "slight problems", 3 = "moderate problems", 4 = "severe problems", and 5 = "extreme problems"). This questionnaire provide a 5-digit score which generate a health state profile. The VAS records the patient\'s self-rated health on a vertical visual analogue scale where the score range from 0 (The best health you can imagine) to 100 (The worst health you can imagine). The VAS is used as a quantitative measure of health outcome that reflects the patient\'s own judgement.'}, {'measure': 'Incidence of Adverse Events', 'timeFrame': 'From randomisation, up to 5 years', 'description': 'Safety and tolerability of the treatment will be evaluated using the National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5). NCI-CTCAE is widely accepted in the community of oncology research as the leading rating scale for adverse events. This scale, divided into 5 grades (1 = "mild", 2 = "moderate", 3 = "severe", 4 = "life-threatening", and 5 = "death") determined by the investigator, will make it possible to assess the severity of the disorders.'}], 'primaryOutcomes': [{'measure': 'Progression-free survival (PFS)', 'timeFrame': 'From randomisation to disease progression or death, up to 5 years.', 'description': 'Time from randomisation to the first documented progression of disease (PD) as assessed by the investigator according to RECIST v1.1, or death from any cause, whichever occurs first.'}], 'secondaryOutcomes': [{'measure': 'Overall Survival (OS)', 'timeFrame': 'From randomisation to death, up to 5 years.', 'description': 'The overall survival is the length of time from randomization that patients enrolled in the study are still alive.'}, {'measure': 'Objective response rate', 'timeFrame': 'From randomisation, up to 5 years.', 'description': 'Objective response rate is defined as the proportion of patients achieving complete response (CR) or partial response (PR) (according to RECIST v1.1). Objective response rate will be presented as the best response achieved compared to the disease assessment performed at randomisation.'}, {'measure': 'Time to treatment failure', 'timeFrame': 'From randomisation to treatment failure event, up to 5 years.', 'description': 'Time from patient starting their allocated treatment to the date at which a patient first experiences a treatment failure event. The following will be considered as treatment failure events: early treatment discontinuation (regardless of reason), disease progression, death, starting a new treatment after completing scheduled treatment, withdrawal from the study due to any reason or loss to follow-up.'}, {'measure': 'Progression-free survival after next line of treatment (PFS2)', 'timeFrame': 'From randomisation to second disease progression or death, up to 5 years.', 'description': 'Time from randomisation to the date of second disease progression or death, whichever occurs first.'}, {'measure': 'Duration of response', 'timeFrame': 'From response to disease progression or death, up to 5 years.', 'description': 'Duration of response is defined as the time from first documented response (compared to baseline measurement taken at randomisation) until the date of disease progression, as assessed by the investigator according to RECIST v1.1, or death from any cause whichever occurs first.'}, {'measure': 'Disease control rate', 'timeFrame': 'From randomisation, up to 5 years.', 'description': 'Disease control rate is defined as the proportion of randomised patients achieving CR, PR, stable disease (SD)/no evidence of disease (NED) as assessed by the investigator according to RECIST v1.1.'}, {'measure': 'Percentage change in tumour size', 'timeFrame': 'From randomisation, up to 5 years.', 'description': 'Taking the measurements at randomisation as the reference.'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Biliary Tract Neoplasms', 'Targeted therapy', 'Personalised medicine'], 'conditions': ['Biliary Tract Neoplasms']}, 'descriptionModule': {'briefSummary': "The object of this trial is to evaluate whether the introduction of a targeted therapy after 4 cycles of the current standard-of-care treatment for advanced biliary cancer is superior to continuing with the standard treatment.\n\nThe trial is composed of two phases: (i) An initial screening phase to identify a suitable patient population, during which a molecular profile of the patient's tumour will be obtained, and (ii) a randomised comparative trial in which patients with disease control after 4 cycles of standard treatment, and whose tumour harbours a targetable molecular alteration, will be randomised (2:1) to receive either a matched targeted therapy or to continue with the standard treatment.", 'detailedDescription': "This is a Phase 3, multicentre, randomised, open-label trial to evaluate whether the introduction of molecular targeted therapy (MTT) as maintenance after 4 cycles of standard-of-care first-line systemic therapy (1L SoC) is superior to continuation of 1L-SoC in the treatment of patients with ABC. The trial is composed of two phases: (i) An initial screening phase to identify a suitable patient population, and (ii) a randomised comparative trial.\n\nThe aim of the screening phase is to identify a medically suitable population, to obtain a molecular profile of the patient's tumour, to collect baseline data concerning patient demographics and disease characteristics and to obtain pre-treatment blood and tumour samples for further translational research.\n\nA genetic profile will be obtained from tumour-derived DNA and RNA samples by next-generation sequencing and from circulating tumour DNA. The trial Molecular Tumour Board will determine whether each patient harbours a targetable molecular alteration for one or more of the trial MTTs.\n\nPatients with disease control after 4 cycles of 1L-SoC, who did not experience limiting toxicity, and whose tumour harbours at least one targetable molecular alteration, will be invited to participate in the randomised phase of the trial in which 159 eligible patients will be randomised (2:1) to receive either maintenance therapy with a matched MTT or to continue 1L-SoC treatment."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "SCREENING PHASE\n\nInclusion Criteria:\n\n1. Signed a written informed consent form prior to any trial specific procedures (Consent #1)\n2. Histologically-proven intrahepatic, perihilar or distal cholangiocarcinoma, or gallbladder carcinoma (ampullary carcinoma excluded)\n3. De novo or recurrent, locally advanced (non-resectable) or metastatic disease\n4. Availability of a suitable archived sample of primary or metastatic tumour tissue (frozen, or FFPE) or able to undergo a biopsy to obtain a suitable malignant tissue sample\n5. Aged ≥18 years\n6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n7. Estimated life expectancy \\>3 months\n8. Candidate for 1L-SoC therapy, or has initiated first cycle of 1L-SoC therapy\n9. Affiliated to a social security system or in possession of equivalent private health insurance (according to local country health provision arrangements).\n\nExclusion Criteria:\n\n1. Contraindication to 1L-SoC\n2. Patients who are candidates for locoregional therapy\n3. Contraindication to tumour biopsy in the absence of suitable archived sample of tumour tissue\n4. Prior anticancer therapy in the palliative setting. Adjuvant capecitabine allowed if completed ≥ 183 days prior to study entry\n5. Received more than 1 cycle of treatment with 1L-SoC\n6. Prior treatment with any of the MTT under investigation in the SAFIR-ABC10 study\n7. Current malignancies (other than ABC), with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin. Cancer survivors, who have undergone potentially curative therapy for a prior malignancy, have no evidence of that disease for 5 years or more and are deemed at negligible risk for recurrence, are eligible for the trial\n8. Any condition which in the Investigator's opinion makes it undesirable for the subject to participate in the trial or which would jeopardize compliance with the protocol\n9. Women who are pregnant or breast-feeding\n10. Patients unwilling or unable to comply with the medical follow-up required by the trial because of geographic, familial, social, or psychological reasons\n11. Individuals deprived of liberty or placed under protective custody or guardianship\n\nRANDOMISED TRIAL\n\nInclusion Criteria:\n\n1. Signed a written informed consent form prior to any trial specific procedures (Consent #2)\n2. Molecular profile showing the tumour harbours at least one targetable molecular alteration with a MTT in the study portfolio (as determined by the trial MTB)\n3. Disease control (stable or responsive) after 4 cycles of 1L-SoC, compared to a pre-treatment disease evaluation, as assessed by the investigator\n4. ECOG performance status of 0 or 1\n5. Presence of at least one evaluable lesion according to RECIST v1.1, or complete response to 12 weeks 1L-SoC\n6. Adequate bone marrow function: absolute neutrophil count (ANC) ≥1.5 × 10⁹/L, platelet count ≥100 × 10⁹/L, and haemoglobin ≥9 g/dL\n7. Adequate liver function: total bilirubin level ≤1.5 × the upper limit of normal (ULN) range (total bilirubin ≤3.0 ULN when the patient has documented Gilbert syndrome), and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels ≤2.5 × ULN (AST and ALT ≤5 ULN when documented tumour liver involvement)\n8. Adequate renal function: estimated creatinine clearance ≥ 60 mL/min according to the Cockcroft-Gault formula\n9. Adequate cardiac function: left ventricular ejection fraction ≥50% at baseline as determined by either echocardiogram or multigated acquisition scan (MUGA)\n10. Adequate biliary drainage, with no evidence of ongoing infection\n11. Men, and women of childbearing potential (WOCBP) must agree to use adequate contraception for the duration of trial participation and as required after completing study treatment. Men must also agree to not donate sperm and women must agree to not donate oocytes during the specified period.\n12. Women of childbearing potential must have a negative serum pregnancy test performed within 3 days before the date of randomisation\n13. Willing and able to comply with the protocol for the duration of the study including scheduled visits, treatment plan, laboratory tests, and other study procedures\n14. Affiliated to a social security system or in possession of equivalent private health insurance (according to local country health provision arrangements)\n\nExclusion Criteria:\n\n1. Disease progression occurring at any time prior randomisation, or toxicity that led to the discontinuation of the 1L-SoC before 4 full cycles have been delivered\n2. Toxicities from 1L-SoC not resolved to Grade ≤ 1 (according to version 5.0 the National Cancer Institute - Common terminology criteria for adverse events \\[NCI-CTCAE v5.0\\]) before randomisation, with the exception of alopecia\n3. Contraindication or known hypersensitivity to the MTT for the molecular alteration found in the patient, or any component in their formulation Note: For patients with multiple target alterations, contraindication to one MTT will not warrant exclusion if MTT to an alternative target is feasible.\n4. Microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) cancers\n5. Major surgery within 4 weeks of randomisation\n6. Radiotherapy within 7 days of randomisation\n7. Untreated central nervous system (CNS) metastases, symptomatic CNS metastases, or radiation treatment for CNS metastases within 4 weeks of start of study treatment. Stable, treated brain metastases are allowed (defined as subjects who are off steroids and anticonvulsants and are neurologically stable with no evidence of radiographic progression for at least 4 weeks at the time of screening).\n8. Clinically significant cardiovascular disease (recent acute myocardial infarction, treated congestive heart failure \\[2 or above on the New York Heart Association functional classification scale\\], recent thromboembolic or cerebrovascular events \\[within 12 weeks, excepted if related to indwelling catheter\\], known prolonged QT syndrome).\n9. Cardiorespiratory pathologies where hyperhydration is contraindicated.\n10. Manifestation of tinnitus and/or hearing loss since initiation of cisplatin therapy.\n11. Known leptomeningeal disease. If leptomeningeal disease has been reported radiographically on baseline magnetic responance imaging (MRI), but is not suspected clinically by the investigator, the subject must be free of neurological symptoms.\n12. Concurrent malignancy (other than ABC), with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin. Cancer survivors, who have undergone potentially curative therapy for a prior malignancy, have no evidence of that disease for 5 years or more and are deemed at negligible risk for recurrence, are eligible for the trial\n13. Concomitant treatment with phenytoin in prophylactic use where this cannot be substituted for another therapy\n14. Known active hepatitis B virus or hepatitis C virus infection or human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome\n15. Any condition which in the Investigator's opinion makes it undesirable for the subject to participate in the trial or which would jeopardize compliance with the protocol\n16. Women who are pregnant or breast-feeding\n17. Participation in another therapeutic trial within the 30 days prior to entering the study. Participation in an observational trial would be acceptable\n18. Patients unwilling or unable to comply with the medical follow-up required by the trial because of geographic, familial, social, or psychological reasons\n19. Individuals deprived of liberty or placed under protective custody or guardianship\n\nADDITIONAL EXCLUSION CRITERIA FOR SPECIFIC MTTs:\n\nPatients assigned to receive oral therapies:\n\n1. Inability or unwillingness to swallow pills\n2. History of malabsorption syndrome or other condition that would interfere with enteral absorption. For example, active intestine inflammation (e.g., Crohn's disease or ulcerative colitis) requiring immunosuppressive therapy\n\nFutibatinib:\n\n1. History and/or current evidence of any of the following disorders:\n\n 1. Non-tumour related alteration of the calcium-phosphorus homeostasis that is considered clinically significant in the opinion of the Investigator\n 2. Ectopic mineralization/calcification, including but not limited to soft tissue, kidneys, intestine, or myocardia and lung, considered clinically significant in the opinion of the Investigator\n 3. Retinal or corneal disorder confirmed by retinal/corneal examination and considered clinically significant in the opinion of the Investigator\n2. Concomitant treatment with strong CYP3A/P-gp inhibitors or strong or moderate CYP3A/P gp inducers where these cannot be substituted for another therapy.\n\nIvosidenib:\n\n1. Patients with history of torsade de pointes\n2. Concomitant treatment with digoxin where this cannot be substituted for another therapy\n3. Patients with a heart-rate corrected QT interval (using Fridericia's formula) (QTcF) ≥ 450 msec or other factors that increased the risk of QT prolongation or arrhythmic events (e.g. heart failure, hypokalemia, family history of long QT interval syndrome)\n4. Concomitant treatment with strong CYP3A4 inducers or dabigatran where these cannot be substituted for another therapy\n5. Concomitant treatment with medicinal products known to prolong the QTc interval, or moderate or strong CYP3A4 inhibitors where these cannot be substituted for another therapy\n6. Familial history of sudden death or polymorphic ventricular arrhythmia.\n7. Hypokalemia, hypomagnesemia or hypocalcemia where this cannot be corrected by supplementation\n\nZanidatamab:\n\n1. Treatment with anthracyclines within 90 days before first dose of zanidatamab and/or total lifetime load exceeding 360 mg/m2 Adriamycin® or equivalent\n2. Use of corticosteroids administered at doses equivalent to \\> 15 mg per day of prednisone within 2 weeks of first zanidatamab dosing unless otherwise approved by the coordinating investigator. Topical, ocular, intra-articular, intranasal, and/or inhalational corticosteroids are permitted\n3. QTcF \\> 470 ms\n4. History of myocardial infarction or unstable angina within 6 months prior to enrollment, troponin levels consistent with myocardial infarction, or clinically significant cardiac disease, such as ventricular arrhythmia requiring therapy, uncontrolled hypertension, or any history of symptomatic congestive heart failure\n5. Acute or chronic uncontrolled pancreatitis or Child-Pugh Class C liver disease\n6. Clinically significant infiltrative pulmonary disease not related to lung metastases\n7. A history of life-threatening hypersensitivity to monoclonal antibodies or recombinant proteins\n\nNeratinib \\& trastuzumab:\n\n1. Patients with severe hepatic impairment (Child-Pugh Class C)\n2. Co-administration with the following medical products that are strong inducers of the CYP3A4/P-gp isoform of cytochrome P450, such as carbamazepine, phenytoin (antiepileptics), St John's wort (Hypericum perforatum) or rifampicin (antimycobacterial)\n3. Patients who are experiencing dyspnoea at rest due to complications of advanced malignancy or co-morbidities\n4. Hypersensitivity to murine proteins\n5. Current active pneumonitis within 90 days of receiving trastuzumab or a known history of interstitial lung disease\n\nEncorafenib \\& binimetinib:\n\n1. Patients with a history or current evidence of retinal vein occlusion or risk factors for retinal vein occlusion (e.g., uncontrolled glaucoma or history of hyperviscosity or hypercoagulability syndrome)\n2. Patients with concurrent neuromuscular disorders associated with elevated creatine phosphokinase (\\>ULN)\n3. Patients with hypokalemia, hypomagnesemia, or hypocalcemia (i.e. Serum potassium, magnesium or calcium \\< lower normal limit)\n4. Patients with a QTcF ≥ 450 msec for men, or ≥ 470 msec for women\n5. Current or expected use of a strong inhibitor of CYP3A4"}, 'identificationModule': {'nctId': 'NCT05615818', 'acronym': 'SAFIR-ABC10', 'briefTitle': 'Personalized Medicine for Advanced Biliary Cancer Patients', 'organization': {'class': 'OTHER', 'fullName': 'UNICANCER'}, 'officialTitle': 'Molecular Targeted Maintenance Therapy Versus Standard of Care in Advanced Biliary Cancer: an International, Randomised, Controlled, Open-label, Platform Phase 3 Trial', 'orgStudyIdInfo': {'id': 'UC-GMP-2201 - PRODIGE 78'}, 'secondaryIdInfos': [{'id': '2022-000190-19', 'type': 'EUDRACT_NUMBER'}, {'id': '2022-502403-30-00', 'type': 'OTHER', 'domain': 'EU-CT'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Experimental', 'description': 'Molecular targeted therapy matched to genetic alteration carried by the tumour', 'interventionNames': ['Drug: Futibatinib', 'Drug: Ivosidenib', 'Drug: Zanidatamab', 'Drug: Trastuzumab', 'Drug: Neratinib', 'Drug: Encorafenib', 'Drug: Binimetinib', 'Drug: Niraparib']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Control', 'description': 'Continued standard of care treatment for first-line biliary tract cancer', 'interventionNames': ['Drug: Cisplatin', 'Drug: Gemcitabine']}], 'interventions': [{'name': 'Futibatinib', 'type': 'DRUG', 'description': 'Dose 20 mg once a day (QD)', 'armGroupLabels': ['Experimental']}, {'name': 'Ivosidenib', 'type': 'DRUG', 'otherNames': ['Tibsovo'], 'description': 'Dose 500 mg QD', 'armGroupLabels': ['Experimental']}, {'name': 'Zanidatamab', 'type': 'DRUG', 'description': 'Dose: Patients \\< 70 kg: 1800 mg every 3 weeks (Q3W), Patients ≥ 70 kg: 2400 mg Q3W', 'armGroupLabels': ['Experimental']}, {'name': 'Trastuzumab', 'type': 'DRUG', 'otherNames': ['Zercepac'], 'description': 'Loading dose 8 mg/kg, then 6 mg/kg Q3W (Combination with neratinib)', 'armGroupLabels': ['Experimental']}, {'name': 'Neratinib', 'type': 'DRUG', 'otherNames': ['Nerlynx'], 'description': 'Dose: 240 mg QD (combination with trastuzumab)', 'armGroupLabels': ['Experimental']}, {'name': 'Encorafenib', 'type': 'DRUG', 'otherNames': ['Braftovi'], 'description': 'Dose: 450 mg QD (Combination with binimetinib)', 'armGroupLabels': ['Experimental']}, {'name': 'Binimetinib', 'type': 'DRUG', 'otherNames': ['Mektovi'], 'description': 'Dose: 45 mg twice a day (BID) (Combination with encorafenib)', 'armGroupLabels': ['Experimental']}, {'name': 'Niraparib', 'type': 'DRUG', 'otherNames': ['Zejula'], 'description': 'Dose: 200 mg QD or 300 mg QD', 'armGroupLabels': ['Experimental']}, {'name': 'Cisplatin', 'type': 'DRUG', 'description': 'Dose: 25 mg/m2 IV on days 1 and 8 Q3W (CISGEM)', 'armGroupLabels': ['Control']}, {'name': 'Gemcitabine', 'type': 'DRUG', 'description': 'Dose: 1000 mg/m2 IV on days 1 and 8 Q3W (CISGEM)', 'armGroupLabels': ['Control']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Brussels', 'status': 'NOT_YET_RECRUITING', 'country': 'Belgium', 'contacts': [{'name': 'Anne DEMOLS, MD', 'role': 'CONTACT'}, {'name': 'Anne DEMOLS, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Cliniques universitaires de Bruxelles - Hôpital Erasme ULB', 'geoPoint': {'lat': 50.85045, 'lon': 4.34878}}, {'city': 'Brussels', 'status': 'NOT_YET_RECRUITING', 'country': 'Belgium', 'contacts': [{'name': 'Ivan BORBATH, MD', 'role': 'CONTACT'}, {'name': 'Ivan BORBATH, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Cliniques universitaires Saint-Luc', 'geoPoint': {'lat': 50.85045, 'lon': 4.34878}}, {'city': 'Edegem', 'status': 'NOT_YET_RECRUITING', 'country': 'Belgium', 'contacts': [{'name': 'Timon VANDAMME, MD', 'role': 'CONTACT'}, {'name': 'Timon VANDAMME, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Universitair Ziekenhuis Antwerpen (UZA)', 'geoPoint': {'lat': 51.15662, 'lon': 4.44504}}, {'city': 'Leuven', 'status': 'NOT_YET_RECRUITING', 'country': 'Belgium', 'contacts': [{'name': 'Jeroen DEKERVEL, MD', 'role': 'CONTACT'}, {'name': 'Jeroen DEKERVEL, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Universitair Ziekenhuis Leuven', 'geoPoint': {'lat': 50.87959, 'lon': 4.70093}}, {'city': 'Amiens', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Vincent HAUTEFEUILE, MD', 'role': 'CONTACT'}, {'name': 'Vincent HAUTEFEUILE, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'CHU Amiens Picardie', 'geoPoint': {'lat': 49.9, 'lon': 2.3}}, {'city': 'Angers', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Carole Vitellius', 'role': 'CONTACT'}, {'name': 'Carole Vitellius, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "CHU d'Angers", 'geoPoint': {'lat': 47.47156, 'lon': -0.55202}}, {'city': 'Angers', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Victor SIMMET, MD', 'role': 'CONTACT'}, {'name': 'Victor SIMMET, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Institut de cancerologie de l'Ouest - Angers", 'geoPoint': {'lat': 47.47156, 'lon': -0.55202}}, {'city': 'Avignon', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Clémence TOULLEC', 'role': 'CONTACT'}, {'name': 'Clémence TOULLEC, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Institut du Cancer Avignon Provence', 'geoPoint': {'lat': 43.94834, 'lon': 4.80892}}, {'city': 'Besançon', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Christophe BORG', 'role': 'CONTACT'}, {'name': 'Christophe BORG, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'CHU de Besançon', 'geoPoint': {'lat': 47.24878, 'lon': 6.01815}}, {'city': 'Bordeaux', 'status': 'NOT_YET_RECRUITING', 'country': 'France', 'contacts': [{'name': 'Jean-Frédéric BLANC', 'role': 'CONTACT'}, {'name': 'Jean-Frédéric BLANC, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'CHU de Bordeaux - Hôpital Haut-Leveque', 'geoPoint': {'lat': 44.84124, 'lon': -0.58046}}, {'city': 'Caen', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Stéphane CORBINAIS', 'role': 'CONTACT'}, {'name': 'Stéphane CORBINAIS, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Centre François Baclesse', 'geoPoint': {'lat': 49.18585, 'lon': -0.35912}}, {'city': 'Clermont-Ferrand', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Florence OSAER-POLYCARPE', 'role': 'CONTACT'}, {'name': 'Florence OSAER-POLYCARPE, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Centre Jean Perrin', 'geoPoint': {'lat': 45.77969, 'lon': 3.08682}}, {'city': 'Clermont-Ferrand', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Marine JARY, MD', 'role': 'CONTACT'}, {'name': 'Marine JARY, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'CHU Estaing de Clermont Ferrand', 'geoPoint': {'lat': 45.77969, 'lon': 3.08682}}, {'city': 'Créteil', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Christophe TOURNIGAND, MD', 'role': 'CONTACT'}, {'name': 'Christophe TOURNIGAND, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'APHP - Hopital Henri Mondor', 'geoPoint': {'lat': 48.79266, 'lon': 2.46569}}, {'city': 'Dijon', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Sylvain MANFREDI', 'role': 'CONTACT'}, {'name': 'Sylvain MANFREDI, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'CHU de Dijon', 'geoPoint': {'lat': 47.31344, 'lon': 5.01391}}, {'city': 'Grenoble', 'status': 'NOT_YET_RECRUITING', 'country': 'France', 'contacts': [{'name': 'Gael ROTH, MD', 'role': 'CONTACT'}, {'name': 'Gael ROTH, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'CHU Grenoble Alpes', 'geoPoint': {'lat': 45.17869, 'lon': 5.71479}}, {'city': 'Grenoble', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Camille HERVE, MD', 'role': 'CONTACT'}, {'name': 'Camille HERVE, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Groupe hospitalier mutaliste de Grenoble - Institut Daniel Hollard', 'geoPoint': {'lat': 45.17869, 'lon': 5.71479}}, {'city': 'Lille', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Aurélien CARNOT, MD', 'role': 'CONTACT'}, {'name': 'Aurélien CARNOT, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Centre Oscar Lambret', 'geoPoint': {'lat': 50.63391, 'lon': 3.05512}}, {'city': 'Lille', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Anthony TURPIN, MD', 'role': 'CONTACT'}, {'name': 'Anthony TURPIN, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'CHU Lille', 'geoPoint': {'lat': 50.63391, 'lon': 3.05512}}, {'city': 'Limoges', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Frédéric THUILLIER, MD', 'role': 'CONTACT'}, {'name': 'Frédéric THUILLIER, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'CHU Dupuytren', 'geoPoint': {'lat': 45.83362, 'lon': 1.24759}}, {'city': 'Lyon', 'status': 'NOT_YET_RECRUITING', 'country': 'France', 'contacts': [{'name': 'Philippe CASSIER, MD', 'role': 'CONTACT'}, {'name': 'Philippe CASSIER, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Centre Leon Bérard', 'geoPoint': {'lat': 45.74906, 'lon': 4.84789}}, {'city': 'Lyon', 'status': 'NOT_YET_RECRUITING', 'country': 'France', 'contacts': [{'name': 'Lea CLAVEL, MD', 'role': 'CONTACT'}, {'name': 'Lea CLAVEL, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Clinique Privée Jean Mermoz', 'geoPoint': {'lat': 45.74906, 'lon': 4.84789}}, {'city': 'Lyon', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Marielle GUILLET, MD', 'role': 'CONTACT'}, {'name': 'Marielle GUILLET, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hospices Civils de Lyon - Croix Rousse', 'geoPoint': {'lat': 45.74906, 'lon': 4.84789}}, {'city': 'Marseille', 'status': 'NOT_YET_RECRUITING', 'country': 'France', 'contacts': [{'name': 'Laétitia DAHAN, MD', 'role': 'CONTACT'}, {'name': 'Laétitia DAHAN, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'APHM - CHU La Timone', 'geoPoint': {'lat': 43.29695, 'lon': 5.38107}}, {'city': 'Marseille', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Nicolas BARRIERE, MD', 'role': 'CONTACT'}, {'name': 'Nicolas BARRIERE, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hôpital Européen', 'geoPoint': {'lat': 43.29695, 'lon': 5.38107}}, {'city': 'Marseille', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Simon LAUNAY, MD', 'role': 'CONTACT'}, {'name': 'Simon LAUNAY, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Institut Paoli Calmettes', 'geoPoint': {'lat': 43.29695, 'lon': 5.38107}}, {'city': 'Montpellier', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Fabienne PORTALES, MD', 'role': 'CONTACT'}, {'name': 'Fabienne PORTALES, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Institut de Cancer de Montpellier', 'geoPoint': {'lat': 43.61093, 'lon': 3.87635}}, {'city': 'Nantes', 'status': 'NOT_YET_RECRUITING', 'country': 'France', 'contacts': [{'name': 'Yann TOUCHEFEU, MD', 'role': 'CONTACT'}, {'name': 'Yann TOUCHEFEU, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'CHU Nantes - Hôtel Dieu', 'geoPoint': {'lat': 47.21725, 'lon': -1.55336}}, {'city': 'Nice', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Ludovic EVESQUE, MD', 'role': 'CONTACT'}, {'name': 'Ludovic EVESQUE, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Centre Antoine Lacassagne', 'geoPoint': {'lat': 43.70313, 'lon': 7.26608}}, {'city': 'Paris', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Mohamed BOUATTOUR, MD', 'role': 'CONTACT'}, {'name': 'Mohamed BOUATTOUR, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'APHP - Hôpital Beaujon', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'city': 'Paris', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Romain CORIAT, MD', 'role': 'CONTACT'}, {'name': 'Romain CORIAT, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'APHP - Hôpital Cochin', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'city': 'Paris', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Helene BOUSSION DESLOGES, MD', 'role': 'CONTACT'}, {'name': 'Helene BOUSSION DESLOGES, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'APHP - Hôpital Saint Antoine', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'city': 'Paris', 'status': 'NOT_YET_RECRUITING', 'country': 'France', 'contacts': [{'name': 'Olivier DUBREUIL, MD', 'role': 'CONTACT'}, {'name': 'Olivier DUBREUIL, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Groupe Hospitalier Diaconesses Croix Saint-Simon', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'city': 'Paris', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'David MALKA, MD', 'role': 'CONTACT'}, {'name': 'David MALKA, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Institute Mutualiste Montsouris', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'city': 'Pau', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Juliette THAURY, MD', 'role': 'CONTACT'}, {'name': 'Juliette THAURY, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'CH de Pau', 'geoPoint': {'lat': 43.31117, 'lon': -0.35583}}, {'city': 'Poitiers', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'David TOUGERON, MD', 'role': 'CONTACT'}, {'name': 'David TOUGERON, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'CHU Poitiers', 'geoPoint': {'lat': 46.58261, 'lon': 0.34348}}, {'city': 'Quimper', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Christophe AGNELLO, MD', 'role': 'CONTACT'}, {'name': 'Christophe AGNELLO, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'CH Cornouaille', 'geoPoint': {'lat': 47.99597, 'lon': -4.09795}}, {'city': 'Reims', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Elia GIGANTE, MD', 'role': 'CONTACT'}, {'name': 'Elia GIGANTE, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'CHU de Reims', 'geoPoint': {'lat': 49.26526, 'lon': 4.02853}}, {'city': 'Reims', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Damien BOTSEN, MD', 'role': 'CONTACT'}, {'name': 'Damien BOTSEN, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Institut Jean Godinot', 'geoPoint': {'lat': 49.26526, 'lon': 4.02853}}, {'city': 'Rennes', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Julien Edeline', 'role': 'CONTACT'}, {'name': 'Julien Edeline, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Centre Eugène Marquis', 'geoPoint': {'lat': 48.11109, 'lon': -1.67431}}, {'city': 'Rouen', 'status': 'NOT_YET_RECRUITING', 'country': 'France', 'contacts': [{'name': 'Frederic DI FIORE, MD', 'role': 'CONTACT'}, {'name': 'Frederic DI FIORE, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'CHU Charles Nicolle', 'geoPoint': {'lat': 49.44313, 'lon': 1.09932}}, {'city': 'Saint-Cloud', 'status': 'NOT_YET_RECRUITING', 'country': 'France', 'contacts': [{'name': 'Cindy NEUZILLET, MD', 'role': 'CONTACT'}, {'name': 'Cindy NEUZILLET, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Institut Curie - Saint Cloud', 'geoPoint': {'lat': 48.84598, 'lon': 2.20289}}, {'city': 'Saint-Herblain', 'status': 'NOT_YET_RECRUITING', 'country': 'France', 'contacts': [{'name': 'Amélie MALLET, MD', 'role': 'CONTACT'}, {'name': 'Amélie MALLET, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Institut de Cancerologie de l'Ouest", 'geoPoint': {'lat': 47.21154, 'lon': -1.651}}, {'city': 'Suresnes', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Jaafar BENNOUNA, MD', 'role': 'CONTACT'}, {'name': 'Jaafar BENNOUNA, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hôpital Foch', 'geoPoint': {'lat': 48.87143, 'lon': 2.22929}}, {'city': 'Toulouse', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Nadim FARES, MD', 'role': 'CONTACT'}, {'name': 'Nadim FARES, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'CHU Toulouse', 'geoPoint': {'lat': 43.60426, 'lon': 1.44367}}, {'city': 'Valence', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Hélène FOISY, MD', 'role': 'CONTACT'}, {'name': 'Hélène FOISY, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'CH Valence', 'geoPoint': {'lat': 44.9256, 'lon': 4.90956}}, {'city': 'Vandœuvre-lès-Nancy', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Marie MULLER, MD', 'role': 'CONTACT'}, {'name': 'Marie MULLER, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'CHRU de Nancy', 'geoPoint': {'lat': 48.66115, 'lon': 6.17114}}, {'city': 'Villejuif', 'status': 'NOT_YET_RECRUITING', 'country': 'France', 'contacts': [{'name': 'Olivier ROSMORDUC, MD', 'role': 'CONTACT'}, {'name': 'Olivier ROSMORDUC, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'APHP - Hôpital Paul Brousse', 'geoPoint': {'lat': 48.7939, 'lon': 2.35992}}, {'city': 'Villejuif', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Antoine Hollebecque', 'role': 'CONTACT'}, {'name': 'Antoine Hollebecque, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Gustave Roussy', 'geoPoint': {'lat': 48.7939, 'lon': 2.35992}}, {'city': 'Birmingham', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Yuk Ting MA, MD', 'role': 'CONTACT'}, {'name': 'Yuk Ting MA, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Queen Elizabeth Hospital', 'geoPoint': {'lat': 52.48142, 'lon': -1.89983}}, {'city': 'Bristol', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Stephen FALK, MD', 'role': 'CONTACT'}, {'name': 'Stephen FALK, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Bristol Haematology and Oncology Centre', 'geoPoint': {'lat': 51.45523, 'lon': -2.59665}}, {'city': 'Cambridge', 'status': 'NOT_YET_RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Pippa CORRIE, MD', 'role': 'CONTACT'}, {'name': 'Pippa CORRIE, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Addenbrooke's Hospital", 'geoPoint': {'lat': 52.2, 'lon': 0.11667}}, {'city': 'Cottingham', 'status': 'NOT_YET_RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Anthony MARAVEYAS, MD', 'role': 'CONTACT'}, {'name': 'Anthony MARAVEYAS, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Castle Hill Hospital', 'geoPoint': {'lat': 52.50243, 'lon': -0.7554}}, {'city': 'Leeds', 'status': 'NOT_YET_RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Alan ANTHONEY, MD', 'role': 'CONTACT'}, {'name': 'Alan ANTHONEY, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "St James's Hospital", 'geoPoint': {'lat': 53.79648, 'lon': -1.54785}}, {'city': 'Liverpool', 'status': 'NOT_YET_RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Daniel PALMER, MD', 'role': 'CONTACT'}, {'name': 'Daniel PALMER, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Clatterbridge Cancer Centre NHS Foundation Trust', 'geoPoint': {'lat': 53.41058, 'lon': -2.97794}}, {'city': 'London', 'status': 'NOT_YET_RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Paul ROSS, MD', 'role': 'CONTACT'}, {'name': 'Paul ROSS, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Guy's & St Thomas' Hospital", 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'city': 'London', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Harpreet WASAN, MD', 'role': 'CONTACT'}, {'name': 'Harpreet WASAN, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hammersmith Hospital', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'city': 'London', 'status': 'NOT_YET_RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Roopinder GILLMORE, MD', 'role': 'CONTACT'}, {'name': 'Roopinder GILLMORE, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Royal Free Hospital', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'city': 'London', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Sheela RAO, MD', 'role': 'CONTACT'}, {'name': 'Sheela RAO, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Royal Marsden Hospital', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'city': 'London', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'John BRIDGEWATER, MD', 'role': 'CONTACT'}, {'name': 'John BRIDGEWATER, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University College London', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'city': 'Maidstone', 'status': 'NOT_YET_RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Justin WATERS, MD', 'role': 'CONTACT'}, {'name': 'Justin WATERS, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Maidstone Hospital', 'geoPoint': {'lat': 51.26667, 'lon': 0.51667}}, {'city': 'Manchester', 'status': 'NOT_YET_RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Mairead MCNAMARA, MD', 'role': 'CONTACT'}, {'name': 'Mairead MCNAMARA, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'The Christie Hospital', 'geoPoint': {'lat': 53.48095, 'lon': -2.23743}}, {'city': 'Northwood', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Vasiliki MICHALAREA, MD', 'role': 'CONTACT'}, {'name': 'Vasiliki MICHALAREA, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Mount Vernon Cancer Centre', 'geoPoint': {'lat': 51.61162, 'lon': -0.42454}}, {'city': 'Nottingham', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Aurora ARVIND, MD', 'role': 'CONTACT'}, {'name': 'Aurora ARVIND, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Nottingham University Hospital', 'geoPoint': {'lat': 52.9536, 'lon': -1.15047}}, {'city': 'Oxford', 'status': 'NOT_YET_RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Paul MILLER, MD', 'role': 'CONTACT'}, {'name': 'Paul MILLER, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Churchill Hospital', 'geoPoint': {'lat': 51.75222, 'lon': -1.25596}}, {'city': 'Peterborough', 'status': 'NOT_YET_RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Ankit RAO, MD', 'role': 'CONTACT'}, {'name': 'Ankit RAO, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'North West Anglia NHS Foundation Trust', 'geoPoint': {'lat': 52.57364, 'lon': -0.24777}}, {'city': 'Sheffield', 'status': 'NOT_YET_RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Ahmad SABBAGH, MD', 'role': 'CONTACT'}, {'name': 'Ahmad SABBAGH, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Weston Park Cancer Centre', 'geoPoint': {'lat': 53.38297, 'lon': -1.4659}}, {'city': 'Southampton', 'status': 'NOT_YET_RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Tim IVESON, MD', 'role': 'CONTACT'}, {'name': 'Tim IVESON, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Southampton General Hospital', 'geoPoint': {'lat': 50.90395, 'lon': -1.40428}}, {'city': 'Swansea', 'status': 'NOT_YET_RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Steve KIHARA, MD', 'role': 'CONTACT'}, {'name': 'Steve KIHARA, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Singleton Hospital', 'geoPoint': {'lat': 51.62079, 'lon': -3.94323}}], 'centralContacts': [{'name': 'Marta Jimenez', 'role': 'CONTACT', 'email': 'm-jimenez@unicancer.fr', 'phone': '+33 (0) 1 44 23 55 58'}], 'overallOfficials': [{'name': 'Malka David, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Institut Mutualiste Montsouris'}, {'name': 'Julien Edeline, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Centre Eugène Marquis'}, {'name': 'Ivan Borbath, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Cliniques universitaires Saint-Luc- Université Catholique de Louvain'}, {'name': 'John Bridgewater, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'University College London Cancer Institute'}, {'name': 'Juan W Valle', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'University of Manchester and The Christie NHS Foundation Trust'}]}, 'ipdSharingStatementModule': {'infoTypes': ['STUDY_PROTOCOL', 'SAP'], 'timeFrame': 'Unicancer will consider access to study data upon written detailed request sent to Unicancer, from 6 months until 5 years after publication of summary data.', 'ipdSharing': 'YES', 'description': 'Unicancer will share de-identified individual data that underlie the results reported. A decision concerning the sharing of other study documents, including protocol and statistical analysis plan will be examined upon request.', 'accessCriteria': 'The data shared will be limit to that required for independent mandated verification of the published results, the applicant will need authorization from Unicancer for personal access, and data will only be transferred after signing of a data access agreement.'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'UNICANCER', 'class': 'OTHER'}, 'collaborators': [{'name': 'Cancer Research UK & UCL Cancer Trials Centre', 'class': 'OTHER'}, {'name': 'Belgian Group of Digestive Oncology', 'class': 'OTHER'}, {'name': 'National Cancer Institute, France', 'class': 'OTHER_GOV'}, {'name': 'Cancer Research UK', 'class': 'OTHER'}, {'name': 'Taiho Oncology, Inc.', 'class': 'INDUSTRY'}, {'name': 'Servier', 'class': 'INDUSTRY'}, {'name': 'Zymeworks BC Inc.', 'class': 'INDUSTRY'}, {'name': 'Accord Healthcare, Inc.', 'class': 'INDUSTRY'}, {'name': 'Pierre Fabre Medicament', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'SPONSOR'}}}}